Chest
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: With the burden of COPD increasing, new treatment strategies to optimize pharmacotherapy include combination therapies with complementary modes of action. This phase 3 trial evaluated efficacy and safety of fixed-dose combinations of aclidinium, a long-acting anticholinergic indicated for maintenance treatment of COPD-associated bronchospasm, and formoterol, a long-acting β2-agonist, in moderate to severe COPD patients. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Dr. D'Urzo has received research, consulting and lecturing fees from GlaxoSmithKline, Sepracor, Schering Plough, Altana, Methapharma, AstraZeneca, ONO pharma, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyePharma, and KOS Pharmaceuticals. Stephen Rennard: Consultant fee, speaker bureau, advisory committee, etc.: Stephen Rennard has received honoraria for lectures from AARC, Almirall, Am Col Osteopathic Physicians, Asan Medical Center, American Thoracic Society, California Society of Allergy, CME Incite, COPD Foundation, Creative Educational Concepts, Dey, Duke University, Forest, France Foundation, HSC Medical Education, Information TV, Lung Association, Novartis (Horsham, Nycomed, Otsuka, PeerVoice, Pfizer, Shaw Science, University of Washington, University of Alabama Birmingham, VA Sioux Falls., Consultant fee, speaker bureau, advisory committee, etc.: Stephen Rennard has also received honorarium for consulting with the following: ABIM, Able Associates, Adelphi Research, Align2Acton, Almirall/Prescott, APT Pharma/Britnall, Astra-Zeneca, American Thoracic Society Beilenson, Boehringer Ingelheim, Boehringer Ingelheim (ACCP), BoomCom, Britnall and Nicolini, Capital Research, Chiesi, Clarus Acuity, CommonHealth, Complete Medical Group, Consult Complete, COPDForum, DataMonitor, Decision Resources, Dunn Group, Easton Associates, Equinox, and Forest., Consultant fee, speaker bureau, advisory committee, etc.: (continued) Frankel Group, Fulcrum, Gerson Lehman, Globe Life Sciences, Guidepoint, Health Advanced, Hoffman LaRoche, Informed, Insyght, KOL Connection, Leerink Swan, M. Pankove, McKinsey, MDRxFinancial, Medimmune, Merck, Novartis, Nycomed, Oriel, Osterman, Peal, Penn Technology, Pennside, Pfizer, PharmaVentures, Pharmaxis, Prescott, Price Waterhouse, Propagate, Pulmonary Reviews, Pulmatrix, Reckner Associates, Recruiting Resource, Roche, Sankyo, Schering, and Schlesinger., Consultant fee, speaker bureau, advisory committee, etc.: (continued) Scimed, Smith Research, Sudler and Hennessey, Summer Street Research, Talecris, Think Equity, UBC, Uptake Medical, Vantage Point Management. Victor Mergel: Employee: Victor Mergel is an employee of Forest Research Institute, Inc. Esther Garcia Gil: Employee: Esther Garcia Gil is an employee of Almirall S.A. Anne Leselbaum: Employee: Anne Leselbaum is an employee of Almirall S.A. Cynthia Caracta: Employee: C. Caracta is an employee of Forest Research Institute, Inc. , Shareholder: C. Caracta is a stockowner and has received stock options from Forest Laboratories, Inc.Aclidinium bromide (Tudorzo/Pressair, Eklira/Genuair, Breo/Ellipta) is approved for the maintenance treatment of COPD-associated bronchspasm. The fixed-dose combination of aclidinium bromide/formoterol fumarate is being developed, but not yet approved, for its commercial use for the treatment of COPD.
-
Thoracic SurgerySESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Surgical treatment for colorectal cancer (CRC) lung metastases requires resection of all malignant lesions. Computed Tomography (CT) findings may not agree with pathological ones. This lack of agreement can result in incomplete resection. The aim of this study was to estimate the determinants of disagreement between findings provided by CT and surgical pathology in patients undergoing removal of CRC lung lesions. ⋯ The following authors have nothing to disclose: Carmen Marron Fernandez, Javier de la Cruz, David Lora, Pablo Gamez, Juan Jose Rivas, Raul Embun, Laureano MolinsNo Product/Research Disclosure Information.
-
Respiratory Support PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To evaluate outcome of weaning failure patients sent home on invasive home mechanical ventilation.(IHMV)METHODS: Overall feasibility,safety,efficacy and cost-effectiveness of 10(n=10) tracheostomised patients unable to wean discharged from Metro Centre for Respiratory Disease on IHMV in the year 2012, were analyzed .Cost-effectiveness was evaluated in terms of cost saved per patient discharged alive, life year saved and cost per year of life saved. The survival was calculated by the 30 days mortality rate. Efficacy was calculated by number of decannulation and discontinuation of IMV. Data was statistically analyzed using χ2 test with level of significance taken at p ≤ 0.05RESULTS: The mean age of the patient population was 72.1±12.84years.Mean duration of hospitalization was 23.7±12.62 days whereas ICU stay was 11.7±6.01 days. Six patients were sent home on BiPAP (S/T mode) with IPAP of 14.4 ± 1.63 cm H2O and EPAP of 6.11 ± 0.8 cm H2O, whereas 3 patients were sent home on BIPAP with AVAPS and one on SIMV(PC mode).Median days patients were followed up at home were 35.8 days with a median duration of usage of MV being 18.6 days. The 30 days mortality was 40% (p=0.188).Two patients required readmission.The cost saved per patient discharged alive, who either died or were readmitted was US$ 16241.72. The life year saved was 0.13(p= 0.361) whereas the cost-per year of life saved was US$ 151662.18. Three(n= 3)patients (30.0%; p= 0.241) were successfully decannulated and continue on IHMV beyond 30 days, two discontinued HMV. ⋯ The following authors have nothing to disclose: Mir Ali, Deepak TalwarNo Product/Research Disclosure Information.
-
Lung Cancer Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Lung cancer remains the leading cause of cancer deaths wordlwide. There is a limited data evaluating overall five years lung cancer survival. The aim of this study is to describe the characteristics of our patients with lung cancer and the five years survival rate in our hospital. ⋯ The following authors have nothing to disclose: Rosa Maria Ortiz Comino, Noemi Burgos Guadix, Rosa Lina De los Santos de Lopez, Ana Dolores Romero Ortiz, Manuel De VegaNo Product/Research Disclosure Information.
-
AsthmaSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: The progression and development of asthma across the menopausal transition has not been thoroughly addressed, or clearly separated from the effects of age. The present study evaluates the effects of menopause on asthma severity, quality of life and healthcare utilization using a propensity score model. ⋯ Suzy Comhair: Grant monies (from sources other than industry): NIH (HL69170) The following authors have nothing to disclose: Joe Zein, Eugene Bleecker, William Busse, William Calhoun, Mario Castro, K. Fan Chung, Raed Dweik, Anne Fitzpatrick, Benjamin Gaston, Elliot Israel, Nizar Jarjour, Wendy Moore, Gerald Teague, Sally Wenzel, Serpil ErzurumNo Product/Research Disclosure Information.